Competition Markets Authority
Date of referral: 27 June 2019
Statutory deadline: 5 February 2020
- (updated 26.11.19)
3 January 2020: Illumina has abandoned its anticipated takeover of PacBio after an in-depth CMA merger probe highlighted serious competition concerns.
- Press release: Illumina/PacBio abandon merger (3.1.20)
Illuminas response to the CMAs remedies working paper
Parties Response to Provisional Findings
Notice of extension of inquiry period
The Inquiry Group has decided to extend the reference period by 8 weeks under section 39(3) of the Enterprise Act 2002. The Inquiry Group aims to complete the inquiry as soon as possible and in advance of this date.
Third party response to notice of possible remedies and provisional findings
Parties response to notice of possible remedies
24 October 2019: The CMA has provisionally found competition concerns as part of its in-depth investigation of the anticipated acquisition between Illumina and PacBio.
- Press release: Illuminas takeover of PacBio raises competition concerns (24.10.19)
Third party submissions
1 August 2019: The issues statement sets out the scope of the inquiry. It outlines initial theories on what might be adversely affecting competition, but it does not set out findings or conclusions. The deadline for submissions on the issues statement is 5pm, Thursday 15 August 2019.
Response to phase 1 decision
Inquiry group appointed
27 June 2019: The CMA has appointed the inquiry group: